BioSpace News Archive

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Asymptomatic individuals can transmit COVID-19. In fact, many cases worldwide are caused by people who are without symptoms.

DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential

Phase 3 trial to evaluate efficacy and safety of AT-527, an oral antiviral for treatment of patients with mild to moderate COVID-19 in outpatient setting

Vifor Pharma and Angion Biomedica Corp., announced completion of enrollment for Angion’s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury.

In its recent report, Transparency Market Research gives intricate details about the global behavioral health market. In recent years, there has been a considerable rise in the number of cases of mental health disorders.

Hutchison China MediTech Limited has initiated a registration-intent Phase II clinical trial of HMPL-689, its highly selective and potent PI3Kδ inhibitor, in China in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma, two subtypes non-Hodgkin’s lymphoma.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021 . First Quarter 2021 Highlights First quarter revenue increased 59% to $9.91 billion . First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.

RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, announced it has closed the second tranche of the investment by MainPointe Pharmaceuticals as outlined in the share purchase agreement signed earlier this year by the parties.

Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size